Ann Lab Med 2019; 39(5): 470-477
Performance Evaluation of the Newly Developed BD Phoenix NMIC-500 Panel Using Clinical Isolates of Gram-Negative Bacilli
Byeol Yi Park , M.T.1,*, Demiana Mourad , M.S.2,*, Jun Sung Hong , Ph.D.1, Eun-Jeong Yoon , Ph.D.1, Dokyun Kim , M.D., Ph.D.1,3, Hyukmin Lee , M.D., Ph.D.1,3, and Seok Hoon Jeong , M.D., Ph.D.1,3
1Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul, Korea; 2Department of Global Health Security, Graduate School of Public Health, Yonsei University, Seoul, Korea; 3Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea
Corresponding author: Dokyun Kim, M.D., Ph.D.
Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Gangnam Severance Hospital, Yonsei University College of Medicine, 211 Eonju-ro, Gangnam-gu, Seoul 06273, Korea
Tel: +82-2-2019-3532, Fax: +82-2-2057-8926, E-mail:
*These authors contributed equally to this article.
Received: December 27, 2018; Revised: February 12, 2019; Accepted: April 21, 2019; Published online: September 1, 2019.
© Korean Society for Laboratory Medicine. All rights reserved.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background: The emergence of carbapenem resistance among gram-negative bacilli (GNB), mediated by carbapenemase production, has necessitated the development of a simple and accurate device for detecting minimum inhibitory concentrations (MICs) and resistance mechanisms, especially carbapenemase production. We evaluated the performance of the BD Phoenix NMIC-500 panel (BD Diagnostic Systems, Sparks, MD, USA) for antimicrobial susceptibility testing (AST) and carbapenemase-producing organism (CPO) detection.
Methods: We used 450 non-duplicate clinical GNB isolates from six general hospitals in Korea (409 Enterobacteriaceae and 41 glucose non-fermenting bacilli [GNFB] isolates). AST for meropenem, imipenem, ertapenem, ceftazidime, and ceftazidime/avibactam, and CPO detection were performed using the Phoenix NMIC-500 panel. Broth microdilution was used as the reference method for AST. The rates of categorical agreement (CA), essential agreement (EA), minor error (mE), major error (ME), and very major error (VME) were calculated in each antimicrobial. In addition, PCR and sequencing were performed to evaluate the accuracy of CPO detection by the BD Phoenix NMIC-500 panel, and the rate of correct identification was calculated.
Results: The CA rates were >90% for all antimicrobials tested with the Enterobacteriaceae isolates, except for imipenem (87.2%). The GNFB CA rates ranged from 92.7% to 100% for all antimicrobials. The ME rates were 1.7% for Enterobacteriaceae and 0% for GNFB. The panel identified 97.2% (243/250) of the carbapenemase-producing isolates.
Conclusions: The BD Phoenix NMIC-500 panel shows promise for AST and CPO detection.
Keywords: Performance, BD Phoenix NMIC-500 panel, Antimicrobial susceptibility testing, Carbapenemase-producing organisms

This Article



Indexed/Covered by